Moreover, EFNA1 combined with MMP13 potentially demonstrated a better diagnostic sensitivity for early-stage GC patients than markers CEA and CA19-9, which are major serum tumor markers in gastrointestinal cancers currently used in clinical practice. This evidence concerns the gene MMP13 and neoplasm.